Compare Apollo Global Management Ord Shs (APO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Moderna, Inc. — how do they compare? Apollo Global Management Ord Shs trades at $140.93 (market cap $81.86B), while Moderna, Inc. trades at $65.14 (market cap $25.42B). The key difference: Apollo Global Management Ord Shs is far larger — about 3.2× Moderna, Inc.'s market cap, and Apollo Global Management Ord Shs pays a 1.62% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| APO | MRNA | |
|---|---|---|
Market Cap | $81.86B | $25.42B |
Sector | Financials | Health |
52-Week High | $152.70 | $81.80 |
52-Week Low | $100.30 | $22.36 |
Enterprise Value | -$169.63B | $21.57B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $138.79, up 5.13% today, near its 52-week high. The stock shows a bullish technical trend with strong analyst support, including 23 buy ratings and a consensus price target of $151.50. Recent Q2 2026 earnings of $2.11 per share missed estimates, but revenue growth and record assets under management of $1.05 trillion highlight operational strength. The company continues expanding in AI infrastructure deals, as noted in recent news.
Outlook remains positive given robust fundraising and perpetual capital growth, though risks include expense pressures and market volatility. The high P/E ratio of 49.92 suggests premium valuation, requiring sustained earnings growth to justify upside. Investors should weigh strong institutional sentiment against execution risks in a competitive asset management landscape.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
